DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models is a research paper published in Journal of Clinical Investigation (2024). On theSindex it has a DataRank of 0. It has been cited 30 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01 CA223220
National Institutes of Health
Grant: UG1 CA233259
Emory University
Grant: Emory Winship Cancer Institute lung cancer research pilot funds
NCI NIH HHS
Grant: R01 CA245386
National Institutes of Health
Grant: 3UG1CA233259-06S1
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
National Institutes of Health
Grant: 5R01CA245386-05
c-Myc modulation and its implications in EGFR-targeted cancer therapy
National Institutes of Health
Grant: 5R01CA223220-06
Modulation of death receptor 4 in EGFR-targeted cancer therapy
FWCI
4.80
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals